Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Initiation
  • News
  • Small Cap

Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies

By Vandana Singh
July 8, 1:58 PM
Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs and LAD-I. 

RCKT

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Price Target
  • Reiteration
  • Small Cap
  • Trading Ideas

Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path

By Vandana Singh
July 8, 12:53 PM
Yesterday, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced data from the new interim analysis of the Phase 3 REGENERATE trial evaluating obeticholic acid in…

ICPT

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Initiation
  • Movers
  • News
  • Price Target
  • Trading Ideas

Why This Small-Cap Stock Is Gaining More Than 10% Today?

By Vandana Singh
July 8, 11:40 AM
Chardan has initiated coverage of Immuneering Corp (NASDAQ:IMRX) with a Buy rating and a price target of $18. Immuneering’s lead candidate, IMM-1-104, an…

IMRX

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • News
  • Small Cap

AbbVie Dumps An Early-Alzheimer’s Candidate Developing In Collaboration With Alector

By Vandana Singh
July 8, 10:54 AM
AbbVie Inc (NYSE:ABBV) has decided to terminate the CD33 collaboration program with Alector Inc (NASDAQ:ALEC), developing AL003 for Alzheimer’s disease as one of…

ABBV

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

Horizon Therapeutics Receives FDA Approval For Uncontrolled Gout Candidate

By Ragothaman Srinivasan
July 8, 9:03 AM
The U.S. Food and Drug Administration (FDA) has approved Horizon Therapeutics’ (NASDAQ: HZNP) supplemental Biologics License Application (sBLA) for expanding the labeling to include KRYSTEXXA (pegloticase) injection co-administered with methotrexate, in patients with uncontrolled gout.

HZNP

Read More
3 minute read
  • Biotech
  • FDA
  • Financing
  • General
  • Health Care
  • Large Cap
  • Management
  • Movers
  • News
  • Offerings
  • Penny Stocks
  • Small Cap
  • Trading Ideas

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

By Vandana Singh
July 8, 8:19 AM
Here's a roundup of top developments in the biotech space over the last 24 hours:

ADCT

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • News
  • Small Cap

ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug

By Vandana Singh
July 8, 7:20 AM
ADC Therapeutics SA (NYSE:ADCT) has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (OTC:BIOVF) for the development and commercialization of…

ADCT

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • News
  • Penny Stocks

RVL Pharma Issues Interim Q2 Sales From Its Droopy Eye Treatment

By Vandana Singh
July 8, 6:33 AM
RVL Pharmaceuticals plc (NASDAQ:RVLP) announced preliminary Q2 FY22 sales from Upneeq of $8.4 million, up 42% sequentially. Upneeq (oxymetazoline hydrochloride…

RVLP

Read More
1 minute read
  • General
  • Health Care
  • M&A
  • News

Inotiv Expands Protein/Peptide Bioanalytical Capabilities With This Deal

By Vandana Singh
July 8, 6:24 AM
Contract research organization Inotiv Inc (NASDAQ:NOTV) acquired Nashville, Tennessee-based Protypia Inc for $11 million. Inotiv specializes in nonclinical and analytical drug discovery,…

NOTV

Read More
1 minute read
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Why iSpecimen Shares Are Gaining Today?

By Vandana Singh
July 7, 11:03 AM
iSpecimen Inc (NASDAQ:ISPC) has added new global biospecimen suppliers to its proprietary Marketplace platform for advancing oncology and cardiovascular disease research.…

ISPC

Posts pagination

Previous 1 … 474 475 476 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service